

6. Dosage allowed/ Quantity limit: The starting weekly dose is 0.4 mg/kg intramuscularly, divided into two doses (0.2 mg/kg twice a week), for a minimum of 12 to 24 weeks until immune reconstitution is achieved.

Then, the dose may be gradually adjusted down to maintain trough ADA activity over 30 mmol/hr/L, trough dAXP level under 0.02 mmol/L, and/or to maintain adequate immune reconstitution based on clinical assessment.

Note: If transitioning from Adagen, see prescribing information.

If all the above requirements are met, the medication will be approved for 6 months.

For reauthorization :

1. Chart notes must show at least one of the following:
 - a) Trough plasma ADA activity level of at least 30 mmol/hr/L
 - b) Trough erythrocyte dAXP levels below 0.02 mmol/L
 - c) Improved lymphocyte counts
 - d) Improved clinical immune status (i.e., fewer/less severe infections compared to baseline); AND
2. Member meets one of the following:
 - a)